Background: Partners of women are increasingly present during childbirth and may be exposed to a traumatic experience. Since parents’ mental health issues (i.e. posttraumatic stress disorder) have been shown to increase the risk of problems in the child’s development, it is important to identify these risk factors. Partners often describe severe postpartum haemorrhage as traumatic.

Aim: Whether witnessing severe postpartum haemorrhage is a risk factor for developing posttraumatic stress disorder in partners.

Background: Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. 

Objective: We evaluated patterns and predictors of change from three efficacy trials of trauma-focused cognitive–behavioral treatments (TF-CBT) among service members (N = 702; mean age = 32.88; 89.4% male; 79.8% non-Hispanic/Latino). Rates of clinically significant change were also compared with other trials. Method: The trials were conducted in the same setting with identical measures. The primary outcome was symptom severity scores on the PTSD Symptom Scale—Interview Version (PSS-I; Foa, Riggs, Dancu, & Rothbaum, 1993).

In a previous issue of Biological Psychiatry, we reported on the efficacy of repeated intranasal oxytocin administration early after emergency department admission in preventing posttraumatic stress disorder (PTSD) symptoms, assessed 1.5, 3, and 6 months posttrauma (1). In a randomized, placebocontrolled trial, we demonstrated beneficial effects in patients with high symptom levels before treatment onset (1,2).